Topical therapies in IBD

Due to misunderstandings about their effectiveness and feasibility, topical (or rectal) therapies with aminosalicylates (5-aminosalicylic acid, 5-ASA) and steroids are often underused in patients with ulcerative colitis (UC). However, many of these patients could be treated solely with rectal/topical therapies, or could benefit from them in combination with oral therapies. We review the evidence for topical therapies containing 5-ASA and budesonide in UC and discuss how these therapies can be optimized in daily practice, thereby improving compliance. Finally, we provide a brief summary of studies on the use of other topical treatments in UC, the results of which were both promising and negative. DOI: https://doi.org/10.1159/000341947 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-76210 Accepted Version Originally published at: Frei, Pascal; Biedermann, Luc; Manser, Christine N; Wilk, Maike; Manz, Michael; Vavricka, Stephan R; Rogler, Gerhard (2012). Topical therapies in inflammatory bowel disease. Digestion, 86(Suppl. 1):36-44. DOI: https://doi.org/10.1159/000341947 Frei & Rogler, Review Topical Therapies in IBD, Digestion 2012 (Version 2012-07-13) 1 Topical therapies in IBD Pascal Frei, Luc Biedermann, Christine Manser, Maike Wilk, Michael Manz, Stephan R. Vavricka, Gerhard Rogler Division of Gastroenterology & Hepatology, University Hospital of Zürich, Zürich, Switzerland Division of Gastroenterology and Hepatology, Claraspital, Basel, Switzerland Triemlispital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland